Abstract library

9 results for "Valk".
#1067 Gemox or Alkylating Agents in Neuroendocrine Tumors? The Help of O6-Methylguanine-DNA Methyltransferase (MGMT) Status?
Introduction: Alkylating agents are the backbone chemotherapy in neuroendocrine tumors (NET). However, gemcitabine associated to oxaliplatine (gemox) has showed interesting activity in a small study.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Chemotherapy
Presenting Author: Anne-Sophie Dussol
#3044 Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)
Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
#130 Lanreotide Autogel for malignant carcinoid syndrome: an 8-year experience
Introduction: Somatostatin analogues provide symptomatic relief in carcinoid syndrome and recently have been shown to inhibit tumor growth in metastatic gastroenteropancreatic neuroendocrine tumors (NETs). Lanreotide compounds are reported to have similar efficacy to Octreotide compounds. There is limited long-term data available on Lanreoitde Autogel.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#1072 Predictive Factors for Antiproliferative Activity of Octreotide LAR in Advanced Neuroendocrine Tumors
Introduction: The antiproliferative activity of Octreotide LAR in Neuroendocrine Tumors(NETs) has been demonstrated by small retrospective studies and confirmed by a prospective phase III trial(PROMID).However,there are limited data about the duration and predictors of response.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Faidon Laskaratos
Keywords: octreotide LAR, NETs
#1126 Long-Term Follow-Up and Survival Data in Progressing Advanced Midgut Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an effective treatment option for advanced Neuroendocrine Tumours (NET), however long term survival data is lacking.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Mehmet Yalchin
Keywords: PRRT, PFS, OS
#1135 The Role of External Beam Radiotherapy in the Management of Advanced Neuroendocrine Tumors
Introduction: Palliative external beam radiotherapy (EBRT) is routinely used to control symptoms and disease progression in metastatic malignancies, but there is limited data in metastatic neuroendocrine tumours (NET).
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Medical treatment - Others
Presenting Author: Dr Mehmet Yalchin
Keywords: EBRT, NET
#1744 Predictors of Survival in Patients with Small Intestinal Neuroendocrine Tumours (SINETs) Associated with Mesenteric Desmoplasia
Introduction: SINETs represent 30-50% of small bowel neoplasms with a rising incidence and can be associated with mesenteric fibrosis (MF)
Conference: 14th Annual ENETS conference 2017 (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Faidon M Laskaratos
Keywords: SINETs
#2904 Prognosis and Management of Advanced Digestive Well-Differentiated Grade 3 Neuroendocrine Tumors (G3 NETs): A NET-CONNECT Study Performed in Four Expert Centers
Introduction: G3 NETs are rare tumors with poorly defined prognosis and management.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Dr Louis de Mestier
#2205 Analysis of MET and RET Expression in Patients with Pancreatic Neuroendocrine Tumors Receiving Everolimus
Introduction: Target therapy has improved the outcome of neuroendocrine tumors (NETs), but little is known about the strategies to overcome the acquired resistance. MET is considered one of the putative mechanisms of resistance. RET is also rearranged in some other endocrine tumors (like thyroid).
Conference: 15th Annual ENETS conference 2018 (2018)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: MD Chiara Alessandra Cella
Authors: Cella C A, Barberis M, Spad F, Pisa E, ...
Keywords: Everolimus, MET, RET